Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Brain PET Scan Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS

NCT02124941
View directory record Official record
Conditions
Cocaine Dependence, Healthy
Interventions
N-acetyl cysteine, [18F]FDG PET scan, 1H MRS, [11C]APP311 PET scan
Drug · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 1, 2026, 1:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Brain Imaging of Cannabinoid Receptors

NCT03204305
View directory record Official record
Conditions
Cannabis Use Disorder, Cannabis Dependence, Continuous
Interventions
11C-OMAR, Cannabis
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 1, 2026, 1:45 PM EDT
Completed Not applicable Interventional

Imaging the Patterns of Breast Cancer Early Metastases

NCT02706964
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron emission tomography/x-ray computed tomography, Magnetic resonance imaging, x-ray computed tomography (CT)
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 110 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Gainesville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 1, 2026, 1:45 PM EDT
Terminated Phase 2 Interventional

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 1, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Study 3: Minocycline Decreases Microglia Activation

NCT02213575
View directory record Official record
Conditions
Hypertension
Interventions
Minocycline
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 1, 2026, 1:45 PM EDT
Recruiting Not applicable Interventional

MRI in High-Grade Glioma Patients Undergoing Chemoradiation

NCT05212272
View directory record Official record
Conditions
High Grade Glioma
Interventions
PET-MRI Brain Scan, Blood draw, Memory testing, Optional lumbar puncture for cerebrospinal fluid collection
Procedure · Diagnostic Test · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 1, 2026, 1:45 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

NCT06289582
View directory record Official record
Conditions
Parkinson Disease
Interventions
[F-18]DPA714 administration IV
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 1, 2026, 1:45 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Neurochemical Mechanisms of the Awake vs. Anesthetized Brain

NCT05435560
View directory record Official record
Conditions
Anesthesia, Healthy
Interventions
Dexmedetomidine, Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Sep 1, 2026, 1:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease

NCT03130036
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
[11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 1, 2026, 1:45 PM EDT
Completed Early Phase 1 Interventional

PET and MRI Imaging of Brain Tumors Using [18F]PARPi

NCT04173104
View directory record Official record
Conditions
Brain Tumor, Brain Cancer
Interventions
PET/MR with [18F]PARPi, [18F]PARPi
Diagnostic Test · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 1, 2026, 1:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Brain mGluR5 Receptors Using [18F]SP203

NCT00538798
View directory record Official record
Conditions
Healthy, Glutamate Receptor, mGlur5 Protein, Excitatory Amino Acid Receptors, Drug Kinetics, PET Scan
Interventions
[18F]SP203
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 1, 2026, 1:45 PM EDT
Completed Not applicable Interventional Results available

Effect of Modulating Gamma Oscillations Using tACS

NCT03412604
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Transcranial Alternating Current Stimulation (tACS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 1, 2026, 1:45 PM EDT
Completed Not applicable Interventional Results available

tACS for Amyloid-β Reduction in Alzheimer's Disease

NCT03290326
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Transcranial Alternating Current Stimulation (tACS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 1, 2026, 1:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

NCT02815917
View directory record Official record
Conditions
D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
Interventions
[18F]FTP PET/CT
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 1, 2026, 1:45 PM EDT
Recruiting Phase 1 Interventional

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

NCT05849467
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
Interventions
89 Zr-Df-crefmirlimab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 1, 2026, 1:45 PM EDT
Not listed Phase 2 Interventional

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

NCT00805636
View directory record Official record
Conditions
Brain Metastases, Solid Tumors
Interventions
2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10), Stereotactic Radio-Surgery (SRS) therapy, Positron Emission Tomography
Drug · Radiation · Procedure
Lead sponsor
Aposense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2010 · Synced Sep 1, 2026, 1:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease

NCT04057807
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LPS
Drug
Lead sponsor
Yale University
Other
Eligibility
55 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 1, 2026, 1:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease

NCT04510168
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
11C-ER176, [F-18]MK-6240, Florbetaben, Magnetic Resonance Imaging
Drug · Other
Lead sponsor
Jose Gutierrez, MD, MPH
Other
Eligibility
50 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 1, 2026, 1:45 PM EDT
Completed Early Phase 1 Interventional

18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis

NCT03930173
View directory record Official record
Conditions
Secondary Malignant Neoplasm of Brain and Cerebral Meninges
Interventions
18F-fluciclovine, PET/CT of the brain
Drug · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 1, 2026, 1:45 PM EDT
Completed No phase listed Observational

Clinical Evaluation of Florbetapir in Primary Progressive Aphasia

NCT04726527
View directory record Official record
Conditions
Primary Progressive Aphasia, Alzheimer Disease, Dementia
Interventions
Florbetapir F 18, Positron Emission Tomography
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 1, 2026, 1:45 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Dynamic Connectivity Under Metabolic Constraints

NCT04840095
View directory record Official record
Conditions
Insulin Resistance, Healthy, Diet Modification, Aging
Interventions
Ketones, Glucose
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 1, 2026, 1:45 PM EDT
Not yet recruiting Phase 1 Interventional

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

NCT06600880
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
Device · Drug · Other + 2 more
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 1, 2026, 1:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1

NCT06129838
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[11C]-CS1P1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 1, 2026, 1:45 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15

NCT06032026
View directory record Official record
Conditions
Tauopathies
Interventions
11C-HY-2-15 PET, brain MRI, Amyloid PET scan, Neurological assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 1, 2026, 1:45 PM EDT